| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.89 M USD | 5.39 M USD | -38.86 M USD | -18.09 M USD | -28.76 M USD | -25.23 M USD | -13.32 M USD | -10.27 M USD | -2.54 M USD | -33.54 M USD | -31.91 M USD | -19.06 M USD |
| Depreciation & Amortization | 1.63 M USD | 42325 USD | 38363 USD | 24202 USD | 26413 USD | 43227 USD | 11137 USD | 2440 USD | 0 USD | 261000 USD | 192000 USD | 126000 USD |
| Stock-Based Compensation | 1.50 M USD | 2.20 M USD | 2.53 M USD | 2.16 M USD | 1.60 M USD | 742031 USD | 462239 USD | 139348 USD | 15832 USD | 2.75 M USD | 2.38 M USD | 885000 USD |
| Capital Expenditures | 385278 USD | 573046 USD | 629430 USD | 63069 USD | 14524 USD | 17625 USD | 0 USD | 11836 USD | 0 USD | 535000 USD | 277000 USD | 225000 USD |
| Cash Flow from Investing | -385278 USD | -573046 USD | -629430 USD | -63069 USD | -14524 USD | -17625 USD | 6.14 M USD | -518836 USD | 9.92 M USD | -418000 USD | -484000 USD | -185000 USD |
| Cash Flow from Financing | 19.28 M USD | 433830 USD | 15.64 M USD | 1.34 M USD | 75.85 M USD | 25.13 M USD | 5.15 M USD | 10.11 M USD | 155000 USD | -7.00 M USD | 57.13 M USD | 64.93 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -10.27 M USD | 4.82 M USD | -39.49 M USD | -18.15 M USD | -28.78 M USD | -25.25 M USD | -13.32 M USD | -10.28 M USD | -2.54 M USD | -34.07 M USD | -32.19 M USD | -19.29 M USD |
Dare Bioscience Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products in women's reproductive health. The company advances a portfolio of differentiated therapies aimed at contraception, fertility, and related conditions, prioritizing women's health and expanding treatment options. Key products in development include Ovaprene, a hormone-free monthly contraceptive ring, and Topical Sildenafil, a treatment for female sexual dysfunction. Operating within the health technology sector, specifically pharmaceuticals, Dare Bioscience Inc. engages in identifying, developing, and bringing innovative solutions to market that address unmet needs in women's health and well-being. Founded in 2005 and headquartered in San Diego, California, the company plays a role in advancing specialized therapies in the reproductive health market.